The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033
Market Overview
- 2023 Market Size: $3.44 billion
- 2024 Projected Market Size: $3.79 billion
- CAGR (2023-2024): 10.2%
The cell and gene therapy clinical trial services market has experienced rapid growth, driven by advances in genetic research and increased demand for personalized treatments. This trend is expected to continue, with significant growth anticipated in the coming years.
Future Market Outlook
- 2028 Projected Market Size: $5.64 billion
- CAGR (2024-2028): 10.4%
In the forecast period, the market will benefit from rising global incidence of genetic and auto-immune diseases, increased funding for gene therapy research, and the adoption of novel technologies. Trends such as AI and machine learning integration, personalized medicine, and technological advancements in gene therapies will drive market growth.
View More On The Cell And Gene Therapy Clinical Trial Services Market Report 2024 –
https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report
Key Drivers and Trends
- Increasing Genetic Disease Incidence: The rise in genetic diseases is a primary driver for market growth. Genetic diseases, which stem from DNA variations, are becoming more prevalent due to factors like enhanced genetic testing and increased occurrences of genetic mutations. Clinical trials for cell and gene therapies are crucial for developing innovative treatments and translating research into clinical practice. For example, cystic fibrosis, a genetic disorder, affects approximately 40,000 people in the U.S. and over 105,000 worldwide, underscoring the need for advanced therapies.
- Innovative Solutions: Companies are leveraging advanced technologies to enhance efficiency in clinical trials. For instance, in April 2023, AmerisourceBergen Corporation introduced the Cell and Gene Therapy Integration Hub. This platform, supported by a CRM system, aims to streamline processes and improve connectivity throughout the therapy development and delivery process, enhancing patient and provider experiences.
- Strategic Acquisitions: Mergers and acquisitions are shaping the market landscape. In January 2024, Kyowa Kirin Co. Ltd. acquired Orchard Therapeutics Limited to expand its portfolio in genetic medicine. Orchard Therapeutics specializes in gene therapies for rare diseases, and this acquisition enhances Kyowa Kirin’s capabilities in addressing unmet medical needs.
Market Segmentation
- By Service:
- Clinical Trial Design and Planning
- Supply and Logistic Services
- Regulatory Affairs and Compliance
- Data Management and Biostatistics
- Site Management and Monitoring
- Other Services
- By Therapy Type:
- Gene Therapy
- Cell Therapy
- Gene Modified Cell Therapy
- By Indication:
- Oncology
- Hematology
- Metabolic Disorders
- Infectious Diseases
- Neurology
- Cardiovascular Diseases
- Musculoskeletal Disorders
- Other Indications
- By End-Use:
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic and Research Institutes
- Other End-Users
Regional Insights
- North America: The largest market in 2023, driven by advanced research infrastructure and high demand for innovative therapies.
Conclusion
The cell and gene therapy clinical trial services market is set for continued rapid growth, fueled by the rising prevalence of genetic disorders, technological advancements, and strategic industry developments. The focus on personalized medicine and the adoption of cutting-edge technologies will play crucial roles in shaping the future of this market.
Request A Sample Of The Global Cell And Gene Therapy Clinical Trial Services Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=15535&type=smp
